Home » Stocks » FRLN

Freeline Therapeutics Holdings PLC (FRLN)

Stock Price: $8.75 USD -0.24 (-2.67%)
Updated May 13, 2021 3:57 PM EDT - Market closed
Market Cap 347.65M
Revenue (ttm) n/a
Net Income (ttm) -96.32M
Shares Out 35.85M
EPS (ttm) -6.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $8.75
Previous Close $8.99
Change ($) -0.24
Change (%) -2.67%
Day's Open 8.75
Day's Range 8.75 - 9.75
Day's Volume 40,813
52-Week Range 8.31 - 21.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapie...

2 weeks ago - GlobeNewsWire

LONDON, April 21, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated ...

3 weeks ago - GlobeNewsWire

Plans to have three AAV gene therapy programs in the clinic by year-end 2021

1 month ago - GlobeNewsWire

LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapie...

1 month ago - GlobeNewsWire

Data demonstrate potential of FLT201 to deliver sustained levels of β-glucocerebrosidase (GCase) variant 85, a proprietary engineered GCase that penetrates target tissues in Gaucher disease

3 months ago - GlobeNewsWire

Freeline Therapeutics Holdings Plc (NASDAQ: FRLN) has modified its FLT180a clinical development plan for Hemophilia B to address feedback received from the FDA regarding the characterization and compara...

3 months ago - Benzinga

LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...

3 months ago - GlobeNewsWire

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...

4 months ago - GlobeNewsWire

Updated dose-ranging data demonstrate potential for full normalization of FIX activity

4 months ago - GlobeNewsWire

LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...

5 months ago - GlobeNewsWire

LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...

6 months ago - GlobeNewsWire

About FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a ... [Read more...]

Industry
Biotechnology
IPO Date
Aug 7, 2020
Stock Exchange
NASDAQ
Ticker Symbol
FRLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is 24.43, which is an increase of 179.20% from the latest price.

Price Target
$24.43
(179.20% upside)
Analyst Consensus: Buy